NAFLD (Non-alcoholic fatty liver disease) is the most common chronic liver disease in the world. NAFLD is associated with cardiovascular disease and type 2 diabetes and poses a large burden on healthcare systems.
This study was a prospective, single-arm, 12-week study to investigate the feasibility of our NAFLD-focused digital health program. Our program supports people to optimize their health through diet, activity, stress and sleep content using behavior change techniques. We wanted to investigate retention, engagement and participant satisfaction, as well as exploring the program’s clinical impact.
We found that, in individuals with NAFLD, cardiometabolic and liver-specific health were improved after the 12-week digital health program. Not only did we see significant weight loss and lower systolic blood pressure, but also a significant reduction in liver fat. We also saw excellent participant engagement, completion, and satisfaction. These data are an exciting first step in showing how our digital health solution can improve outcomes for people living with this liver disease.
I was surprised to see those good results after only 12 weeks’ intervention. The digital health program was appreciated independent of age and gender. This health program will be an important tool for our patients with NAFLD to improve their health outcomes.
Sigridur Björnsdottir, MD, PhD, The Reykjavik Heart Center, Iceland.
These results show us that the SK-241 digital health program can be a game-changer in the management of people with NAFLD, both with respect to improving liver-related health in addition to improving overall cardiometabolic health, which is so important for these individuals.
Hildigunnur Ulfdottir, MD, Medical Lead at Sidekick Health.
Check out our beautiful poster from the American Heart Association’s EPI|Lifestyle 2023 conference here.